Stay updated on TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer’s site revision label changed from v3.7.2 to v3.8.0, while the study record remains unavailable on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-30T10:59:29.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    A banner was added announcing NIH website updates and a terminology transition. The site revision changed from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-23T10:59:56.000Z thumbnail image
  4. Check
    31 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision updated from v3.7.0 to v3.7.1; the study page remains an error page.
    Difference
    0.2%
    Check dated 2026-10-09T11:24:15.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The study record page now renders a 403 Forbidden error instead of the full study details. The page displays a minimal header with a Home link, indicating the content is currently inaccessible due to access restrictions.
    Difference
    22%
    Check dated 2026-09-25T13:26:20.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    UI label capitalization for the contact information was adjusted. A new Revision: v3.7.0 marker was added, and several related topics entries (including Melanoma and MedlinePlus Genetics) were removed.
    Difference
    0.2%
    Check dated 2026-09-18T12:32:35.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.5 to v3.6.6, indicating a small update to the page's version history.
    Difference
    0.0%
    Check dated 2026-08-28T11:44:41.000Z thumbnail image

Stay in the know with updates to TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.